11:00 AM EST - Sirona Biochem Corp. : Announced today that partner Jiangsu Wanbang Biopharmaceuticals has confirmed an Investigational New Drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor. The application will be reviewed by the CFDA for acceptance into clinical trials. Wanbang has confirmed it is processing a $500,000 U.S. payment to Sirona Biochem. Sirona Biochem Corp.
shares V.SBM are trading up $0.005 at $0.11.
